STOCK TITAN

Inspira Tech - IINNW STOCK NEWS

Welcome to our dedicated page for Inspira Tech news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Tech stock.

Overview

Inspira Technologies is a specialty medical device company that focuses on developing breakthrough respiratory support technology. The company is dedicated to addressing the critical challenges associated with respiratory failure and invasive mechanical ventilation, leveraging advanced intravascular oxygenation to provide a safer, non-invasive alternative. With a robust portfolio of proprietary technologies, Inspira Technologies is strategically positioned in the life support and respiratory treatment arena, serving a vital role in transforming clinical approaches in critical care settings.

Technology and Innovation

The core of Inspira Technologies lies in its commitment to scientific innovation. The company has developed the INSPIRA ART system—a groundbreaking solution designed to elevate oxygen saturation levels and reduce carbon dioxide in the blood without the complications of traditional mechanical ventilation. Utilizing sophisticated nano-vesicle technology and advanced real-time monitoring through its HYLA blood sensor, the system offers a nuanced approach to respiratory support. Additionally, the innovative VORTX orbiting oxygenation delivery system represents a paradigm shift by promoting natural blood flow with minimal disruption to blood components.

Clinical Impact and Patient Care

In the realm of critical care, Inspira Technologies addresses a significant clinical need. The devices are engineered to stabilize patients experiencing acute respiratory failure, potentially reducing the need for invasive procedures. By maintaining optimal oxygen levels and mitigating the risk of blood damage typically associated with fiber-based oxygenators, the technology provides clinicians with reliable data and enhanced patient safety. Importantly, the system is designed so that patients can remain awake during treatment, facilitating improved clinical observation and more immediate adjustments based on continuous blood monitoring.

Market Position and Strategic Distribution

Operating within a vast and competitive market, Inspira Technologies targets major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The company’s business model integrates both the sales of core devices and a range of compatible disposable kits, which are designed to generate recurring revenue. Strategic collaborations with established distributors and healthcare institutions, such as distribution agreements with Glo-Med, enhance its market penetration and customer support capabilities. This collaborative approach ensures that leading medical centers and critical care units have ready access to their state-of-the-art respiratory solutions.

Operational Strategy and Industry Leadership

Inspira Technologies is firmly rooted in its scientific and clinical expertise. By consistently advancing its research and development efforts, the company demonstrates a commitment to improving patient outcomes and operational efficiency in critical care environments. The integration of real-time monitoring systems and user-centric design in their products reflects a deep understanding of clinical workflows and the pressing need for safety and efficacy in respiratory treatment procedures. Their operational strategy, which includes rigorous design processes, continual assessment of clinical feedback, and an emphasis on scalable manufacturing partnerships, underlines their authoritative stance in the life support technology sector.

Conclusion

Inspira Technologies exemplifies a blend of medical innovation and operational excellence. Through its breakthrough Augmented Respiration Technology and the incorporation of state-of-the-art monitoring systems, the company not only challenges the conventional use of mechanical ventilators but also redefines the approach towards respiratory support. Its holistic strategy—spanning product development, clinical integration, and strategic distribution—positions Inspira as a distinctive, knowledgeable, and trusted entity in the medical technology landscape.

Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. receives U.S. Patent approval for orbiting blood oxygenation delivery system, a core technology of the INSPIRA ART500 device. The system is designed to revolutionize medical oxygenation by eliminating damage caused by fiber membranes. CEO Dagi Ben-Noon hails it as a monumental advancement in blood oxygenation technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.16%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has announced a non-binding Letter of Intent (LOI) with Shamir Medical Center to assess the integration and performance of the INSPIRA™ ART100 device within the hospital's clinical environment. The LOI solidifies the mutual commitment of both parties to evaluate the device's fit, efficiency, and overall impact on healthcare delivery. The collaboration aims to enhance life-support care and establish a pathway for adoption in local and international markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.66%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has announced a summary distribution agreement with Glo-Med Networks, Inc. to potentially provide $32.6 million over a 5-year period. The agreement designates Glo-Med as the exclusive distributor in Saudi Arabia, United Arab Emirates, and Bahrain for the INSPIRA™ ART devices. The agreement is subject to regulatory approvals and is seen as a significant step for both companies in broadening their range of innovative products in the healthcare market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) announces the development of a single-use disposable blood oxygenation kit for its INSPIRA ART medical device series, targeting FDA authorization in 2025. The kit is designed to be compatible with various life support machines, potentially reducing hospital costs. CEO Dagi Ben-Noon anticipates revenue streams based on the disposable razorblade business model, along with the FDA clearance of the INSPIRA™ ART100 device in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) has signed a non-binding Letter of Intent with Northwestern Memorial Hospital, a top-ranked hospital in the United States, to explore collaboration for the evaluation of its INSPIRA ART100 device. The agreement is subject to FDA clearance and entering a definitive evaluation agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) has closed a registered direct offering of 3,031,250 ordinary shares at a purchase price of $1.28 per share, with aggregate gross proceeds of approximately $3.88 million. The company also issued warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.43%
Tags
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) has entered into a definitive agreement for the issuance and sale of 3,031,250 ordinary shares at a purchase price of $1.28 per share in a registered direct offering. The company will also issue unregistered warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.86%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (NASDAQ: IINN) Announces Breakthrough in Sensor Technology for Real-Time Blood Monitoring
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.86%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) is set to attend the 42nd Annual J.P. Morgan Healthcare Conference in January 2024. The Company's CEO and President will meet with medical device and strategic consulting companies, aiming to advance their groundbreaking life support technology. The expected FDA clearance for their innovative life support device that directly oxygenates blood is a significant milestone on the horizon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil, a distinguished specialist in cardiac surgery and intensive care medicine, is expected to significantly contribute to the deployment of the INSPIRA™ ART100. U.S. Food and Drug Administration (FDA) approval is expected in the first half of 2024. The company is leading the way in transforming life-support care, with innovative solutions that pave the way for direct blood oxygenation and AI-driven monitoring systems, potentially enhancing patient outcomes and streamlining hospital operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management clinical trial

FAQ

What is the current stock price of Inspira Tech (IINNW)?

The current stock price of Inspira Tech (IINNW) is $0.2352 as of April 7, 2025.

What is the core focus of Inspira Technologies?

Inspira Technologies specializes in developing innovative respiratory support devices that offer a non-invasive alternative to mechanical ventilation, targeting acute respiratory failure.

How does Inspira Technologies differ from traditional mechanical ventilation?

Their devices utilize proprietary intravascular oxygenation technology and real-time blood monitoring, aiming to maintain adequate oxygen levels without the complications associated with invasive ventilation.

What are the primary technologies developed by the company?

The company’s portfolio includes the INSPIRA ART system, HYLA blood sensor for continuous monitoring, and the VORTX oxygenation delivery system, each designed to optimize patient care.

Which markets does Inspira Technologies serve?

Inspira operates in major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, focusing on advanced respiratory care.

How does the company enhance patient safety?

The technology is designed to reduce blood trauma and complications by using a non-invasive oxygenation process, allowing patients to remain awake and reducing risks typically seen with mechanical ventilation.

What is the company's approach to distribution and market penetration?

Inspira partners with established distributors and healthcare institutions, such as Glo-Med, to ensure efficient deployment and ongoing support in clinical settings.

What sets Inspira’s technology apart in the critical care industry?

Their innovative approach combines advanced nano-vesicle oxygenation with real-time blood monitoring, offering a flexible and safer option for respiratory support that minimizes invasive procedures.

Where can investors find more detailed information about Inspira Technologies?

Investors can review the company’s detailed disclosures and public filings for comprehensive insights into its technology, operational strategy, and market presence.
Inspira Tech

Nasdaq:IINNW

IINNW Rankings

IINNW Stock Data

24.25M
Medical Devices
Healthcare
Link
Israel
Ra'anana